Lindsay (LNN): Weaker than expected margins drive earnings disappointment; long-term outlook for irrigation favorable, but expectations still high -- FY11 EPS cut at Wedbush
Wedbush notes LNN issed on EPS as a result of what appears to be an 800 basis point decline in infrastructure margins. In the absence of significant high margin QMB business, gross margins declined 280 bps YoY. They believe caution is in order given lower than expected margins in the most recent quarter, the unpredictable nature of the infrastructure market, and the volatility in the agriculture segment. Their channel checks continue to support a healthy recovery for the irrigation market. They are reducing their FY11 EPS to $1.96 from $2.26, and reducing their Q2 EPS est to $0.56 from $0.61 (cons: $2.22, $0.65), to account for lower margins in the infrastructure business.
Hetkel ei ole ettevõtte kohta mitte ühtki osta soovitust, enamusel väljas hoia, samas targetid valdavalt alla hetke turuhinna.
Päeva käive on madal ja spread suur, seega peab olema ettevaatlik.
ROVI taastumise taga see, et osad analüütikud arvamas, et "great strategic fit" ja plaplapla.
Mina arvan, et kuna mõlemad on suhteliselt retarded firmad, siis sobivad hästi kokku jah.
Kas ROVI post ei läinud üles enne turu avanemist?
Alari annab väärt infot aga seda tuleb osata lugeda ja kasutada. Ise alles õpin :)
Teema läbi.
Repros Therapeutics (RPRX) Submits Data to the FDA Supporting Morning Assessment of Testosterone for Men Treated with Androxal® as Indicative of Average and Maximum Levels Attained
- submitted to the FDA data collected from three different studies which the Company believes demonstrates that the assessment of testosterone levels between 8 and 10 in the morning is indicative of the maximum and average levels of the male hormone achieved during a particular day following the administration of Androxal. In the Type B meeting held on November 8, 2010, and reported in the Companys press release of November 9, 2010, the FDA stated the preferred method to determine testosterone levels in treatments designed to replace the hormone is a 24 hour assessment.
- Using the data from the 002 and 003 studies the sponsor has determined that a single total testosterone assessment made between 8 and 10 in the morning correlates to the average of the values of the testosterone measurements for a given subject on a given day (correlation coefficient roughly 0.9 for the times 8, 9 and 10, p value < 0.001).
- From the 018 study that assessed men at baseline and after 14 days of treatment, the Company observed that Androxal raises each time point testosterone level by an average of 200 ng/dl at 12.5 mg and 260 ng/dl at a 25 mg dose.
- Unlike topical testosterone preparations, Androxal maintains the normal daily rhythm of testicular testosterone production with peak levels generally occurring in the morning and trough levels exhibited in the evening
Veeco Instruments Inc Hearing recent strength attributed to positive comments from Deutsche Bank on LED industry MOCVD orders
Aktsia hetkel kauplemas protsendi jagu languses $6.78 tasemel.
Teva Pharmaceutical Industries Ltd (TEVA) FDA Issues Complete Response Letter for Lower-Volume Glatiramer Acetate sNDA
The complete response letter stated that the FDA could not approve the application as submitted.
- The FDA noted that the 0.5mL formulation contained the same active ingredient as the currently marketed Copaxone, but that because the mechanism of action of Copaxoneis not fully understood, even a formulation change could impact clinical outcomes. The Agency stated, Unless you can provide a convincing argument that the new higher concentration/lower volume formulation does not have an impact on efficacy, an adequate and well controlled efficacy study will be needed to support efficacy of this new formulation."
- This response supports Teva's belief that even slight changes to a glatiramoid like Copaxonecan significantly and unpredictably influence the efficacy, toxicity and immunogenicity profile of the compound. Teva intends to continue working closely with the FDA to determine the most appropriate next steps regarding the application.
Analog Devices Inc (ADI) ITC ruled in favor of Analog Devices in its lawsuit against Knowles Electronics.
- Judge concluded that Knowles infringes valid claims from one of ADIs Wafer Anti-Stiction Application (WASA) patents. Specifically, he ruled that Knowles infringes claims 2, 3, 4, 5, 6 and 8 from ADIs U.S. Pat. No. 7,364,942. As a result, ADI expects the ITC to issue an exclusion order prohibiting Knowles and its U.S. Distributor from importing or selling all infringing microphones in the United States. Additionally, ADI expects to recover damages on all past sales of Knowles microphones through its pending lawsuit against Knowles in Delaware.
- This recent ruling follows ITC Judge Rogers ruling on November 22nd when he found Knowles Electronics MEMS microphone packaging patents were invalid, a ruling consistent with the position taken by the U.S. Patent and Trademark Office, where all of Knowles asserted claims were rejected in separate reexaminations
Homme 24.dets on USA turud suletud ja kauplemist ei toimu.
Häid jõule kõigile!
LHV meeskond
Fitch on enne pühasid selgelt aktiviseerunud ning päeval langetas reitinguagentuur ka Ungari krediidireitingu alla investment grade ehk BBB- tasemele, väljavaade jäeti aga negatiivse peale. Kui rääkida üldiselt Ungarist, siis allolev graafik Goldmanilt peegeldab hästi riigi majapidamiste probleeme. Kui lõppeva aasta suvel moodustas HUFis väljastatud võlg (liisingud, majalaenud, jne.) ca 12% SKPst, siis välisvaluutas väljatatud võlg ulatus koguni 50%le SKPst. Suur osa välisvaluutas väljastatud võlast on aga just Šveitsi frankides, mis on tänavu HUFi vastu tõusnud 21% - võla suurus on tublisti kasvanud. Augustis keelati näiteks Ungaris ära hüpoteeklaenude väljastamine välisvaluutas. Teatavasti on Ungari ära öelnud ka IMFi abist.
